SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Update on Merck’s HCV Program- Mike RobertsonView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Long term follow-up after treatment with Ombitasvir/Paritaprevir/ritonavir ±Dasabuvir ±Ribavirin in the AMBER – real world experience study- Dr. R. FlisiakView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017When are we done? How long do we follow patients with advanced fibrosis or cirrhosis after SVR? (not available)- Paul PockrosView Slideset
TATarik AsselahMD, PhDSlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Pan-genotypic direct-acting antiviral agents: Opportunity to achieve HCV elimination- Tarik AsselahView Slideset
JFJordan FeldMD, MPHSlidesetViral Hepatitis and Liver DiseaseHEP DART 2017DAA Controversies: Do they Cause HBV Reactivation and/or HCC?- Jordan Feld, MD, MPHView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Management of HCV in Decompensated liver disease- Michael MannsView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Eliminating HCV Transmission by Enhancing Care and Treatment Among HCV/HIV Co-infected Individuals in Australia (not available)- Joseph Doyle, MDView Slideset
MSMark SulkowskiMDSlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Clinical Challenges in HCV infection- Mark Sulkowski, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Controlling HBsAg as a Key Component of a Combination Strategy to Affect an HBV Cure- Michael Sofia, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Studies of the HBV-immune modulator AIC649 (not yet available)- Helga Rübsamen-schaeffView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Immunotherapy is coming for HCC- Spiros Hiotis, MD, PhDView Slideset
SLStephen LocarniniBSc(Hons), PhD, MBBS, FRC(Path)SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017SB 9200: A novel RIG-I agonist for chronic hepatitis B- Stephen Locarnini, BSc(Hons), PhD, MBBS, FRC(Path)View Slideset
